ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2020
Evaluation of EUCAST rapid antimicrobial susceptibility testing (RAST) directly from blood culture bottles.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- RAST+: pre-positivity application of EUCAST RAST using BACTEC FX growth detection plots - a proof-of-concept study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Evaluation of VITEK 2 and three protocols for direct susceptibility testing on Gram-negative bacilli from positive blood culture bottles.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Rapid AST in practice - a workflow analysis of the QuickMICFrontiers in cellular and infection microbiology · 2026Article
- Multicenter evaluation of the QuickMICEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Evaluation of EUCAST rapid antimicrobial susceptibility testing (RAST) for carbapenemase-producing Klebsiella pneumoniae with focus on KPC variants.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Spectral Precision: Recent Advances in Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry for Pathogen Detection and Resistance Profiling.Microorganisms · 2025Review
- Development and evaluation of a direct disk diffusion, rapid antimicrobial susceptibility testing method from blood culture positive for Gram-negative bacilli using rapid molecular testing and microbiology laboratory automation.Microbiology spectrum · 2025Article
- Evaluation of the QIAstat-Dx BCID GN and GPF kits for direct identification and antimicrobial resistance prediction from blood culture bottles.Journal of clinical microbiology · 2024Article
- Bacterial Infections in Intensive Care Units: Epidemiological and Microbiological Aspects.Antibiotics (Basel, Switzerland) · 2024Review
- Usefulness of EUCAST rapid antibiotic susceptibility breakpoints and screening cut-off values directly from blood cultures for the inference of β-lactam resistance mechanisms in Enterobacterales.JAC-antimicrobial resistance · 2023Article
- Multicentre Evaluation of the EUCAST Rapid Antimicrobial Susceptibility Testing (RAST) Extending Analysis to 16-20 Hours Reading Time.Antibiotics (Basel, Switzerland) · 2022Article
- Evaluation of the EUCAST Rapid Antimicrobial Susceptibility Test forJournal of clinical microbiology · 2022Article
- Usefulness of BioFire FilmArray BCID2 for Blood Culture Processing in Clinical Practice.Journal of clinical microbiology · 2021Article
- EUCAST rapid antimicrobial susceptibility testing (RAST) in blood cultures: validation in 55 European laboratories.The Journal of antimicrobial chemotherapy · 2020Article
- Evaluation of EUCAST rapid antimicrobial susceptibility testing (RAST) directly from blood culture bottles.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Article
- Systematic Comparison of Four Methods for Detection of Carbapenemase-ProducingJournal of clinical microbiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was performed to evaluate EUCAST blood culture (BC) rapid antimicrobial susceptibility testing (RAST) for Gram-negative organisms. Clinical BCs positive with Gram-negative-bacilli between April 23, 2019 and June 21, 2019, and 41 spiked isolates were tested by RAST against ceftazidime, piperacillin-tazobactam, meropenem, ciprofloxacin, gentamicin, and amikacin and compared against the routine method, Vitek 2. Vitek turnaround time was also audited. A total of 194 isolates were included, of which 68 Escherichia coli, 47 Klebsiella pneumoniae, and 33 Pseudomonas aeruginosa were further analyzed. For those with interpretable results, using CLSI M52 defined cutoffs for equivalence in antimicrobial susceptibility testing (VME ≤ 1.5%, ME ≤ 3.0%, CA ≥ 90%), RAST was considered equivalent to Vitek 2 for all reading times for the following drug-bug combinations: E. coli (meropenem, gentamicin, and amikacin); K. pneumoniae (ceftazidime, ciprofloxacin, and gentamicin); and P. aeruginosa (gentamicin). The highest error rates were MEs in piperacillin-tazobactam for E. coli at 4 h (5/9, 55.6%) and P. aeruginosa at 6 h (1/1, 100%). The number of MEs/VMEs for other drug-bug combinations and readings times ranged from 0 to 2 isolates (maximum of 7.7%). Median turnaround time to availability of Vitek results was 19.58 h for E. coli (IQR: 17.38-21.38 h), 19.43 h for K. pneumoniae (IQR: 17.72-20.67 h), and 23.3 h for P. aeruginosa (IQR: 21.32-24.35 h). Introduction of RAST shortens turnaround time to results. With the exception of piperacillin-tazobactam, the absolute number of errors was low. A larger-scale evaluation is required to confirm the suitability of implementing this testing method in local laboratories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.